Dr. David R. Karp, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 98
Licensed in Texas since 1991, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: Washington University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
TX license H9655 (first issued 1991; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ut of Texas Southwestern University Hospital - William P. Clements Jr. Dallas, TX
- Parkland Health & Hospital System Dallas, TX
Medical groups
- University of Texas Southwestern Medical Center at Dallas (3,187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 98
- Services billed
- 195
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 74 | 46 |
| Established patient office or other outpatient visit, 20-29 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Dallas, TX | 60 |
| Methotrexate (methotrexate sodium) Other prescribers in Dallas, TX | 50 |
| Hydroxychloroquine Sulfate Other prescribers in Dallas, TX | 47 |
| Gabapentin Other prescribers in Dallas, TX | 34 |
| Duloxetine Hcl Other prescribers in Dallas, TX | 27 |
| Allopurinol Other prescribers in Dallas, TX | 26 |
| Pregabalin Other prescribers in Dallas, TX | 26 |
| Rinvoq (upadacitinib) | 25 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Dallas, TX | 23 |
| Actemra Actpen (tocilizumab) | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $72.13 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $72.13 |
|---|
| Food and Beverage | $72.13 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $117,115 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)
E.r. Squibb & Sons, L.l.c. - A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus
Novartis Pharmaceuticals Corporation - Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN
Genentech, Inc. - Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
E.r. Squibb & Sons, L.l.c. · Completed · NCT03920267
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.